Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) is a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

CIDP is an inflammatory disorder affecting the peripheral nerves, leading to progressive weakness, numbness, and tingling in the limbs. If untreated, symptoms persist and worsen over time.

CJ BIO's BiomeNrichtm POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Corient Private Wealth LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 14.7% in the 4th quarter, ...

Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, increased customer satisfaction, and successful product ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Treatment with efgartigimod PH20 subcutaneous injection can effectively reduce the risk of chronic inflammatory demyelinating polyneuropathy (CIDP) recurrence, according to the results of 2 clinical ...